P
Pulmocide
Focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract
About Pulmocide
Pulmocide is a healthcare startup that specializes in the development of innovative inhaled medicines for the treatment of severe respiratory diseases. Their primary focus is on patients suffering from invasive pulmonary aspergillosis, a serious lung condition, who are not responding well to current antifungal treatments. Pulmocide's lead product is currently in Phase 3 clinical trials, which is the final stage before a new drug can be approved for public use.
Read full description
The company operates in the pharmaceutical industry, specifically in the respiratory disease treatment market. Their business model revolves around the research, development, and commercialization of novel inhaled medicines. They generate revenue through the successful development and subsequent sales of these drugs.
The team at Pulmocide is made up of experienced professionals who have a proven track record in various aspects of the pharmaceutical industry, including clinical development, product approval, manufacturing, business development, finance, and product launch. They are committed to bringing their lead product, opelconazole, to patients who are in desperate need of effective treatment options.
At a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- London, United Kingdom
- Employees
- 20
- Open positions
- None listed
- Dealroom signal
- 63.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Respiratory, Biotech and Pharma, uk is8 life sciences, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Pulmocide.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Dec 2022 | $52M | $460M | SR One · IP Group · Johnson & Johnson Innovation · SV Health Investors | ↗ |
| SERIES COther financing | May 2021 | $92M | $368M | SR One · Johnson & Johnson Innovation · SV Health Investors · Adjuvant Capital | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Pulmocide is 1.7K monthly website visits, up 0% over the last three months. Pulmocide's team declined 41.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Imperial Innovations
SV Life Sciences
F-Prime
Johnson & Johnson Innovation
SR One
Johnson & Johnson
Touchstone Innovations
Series B and later9 investors entered at this stage
Jeito Capital
SV Health Investors
Adjuvant Capital- LCLongwood Capital
IP Group
Pictet
Vivo Capital
Longwood Fund
Cystic Fibrosis Foundation
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Pulmocide on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Pulmocide’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.